(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

The National Agency for the Control of AIDS (NACA) is set to host a high-level meeting to deliberate on sustainable ...

Nigeria must take bold steps to ensure that HIV prevention, treatment, and support remain accessible and resilient, ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

The report emphasises the urgent need for countries to implement radical changes in their HIV programming and funding ...

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

Shahin Davoudpour, PhD, MA, MA, talked with Physician’s Weekly about using social network strategies to improve pre-exposure prophylaxis awareness and uptake.

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV ...

Only 17,000 Ugandans to benefit from $1.1m Global Fund support as officials warn of high demand for long-acting prevention ...